Lozaarc-H Tablet contains a combination of Losartan 50 mg and Hydrochlorothiazide 12.5 mg, formulated for the management of hypertension. Losartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased plasma volume and peripheral resistance. The synergistic effect of these agents provides effective blood pressure control, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Lozaarc-H is indicated for patients whose blood pressure is not adequately controlled with monotherapy. It is essential to monitor renal function, electrolytes, and blood pressure regularly during treatment. Caution is advised in patients with impaired renal or hepatic function, electrolyte imbalances, or hypersensitivity to sulfonamides. Common adverse effects may include dizziness, hypotension, hyperkalemia, and electrolyte disturbances. Lozaarc-H should be used under medical supervision with appropriate dose adjustments based on clinical response and tolerability.